Human Gene Therapy
Human Gene Therapy is the premier, multidisciplinary journal covering all aspects of gene therapy. The Journal is divided into three parts. Human Gene Therapy, the flagship, is published 12 times per year. HGT Methods, a bimonthly journal, focuses on the applications of gene therapy to product testing and development. New in 2013, HGT Clinical Development, a quarterly journal, will serve as a venue for publishing data relevant to the regulatory review and commercial development of cell and gene therapy products. This unique three part program provides 22 issues of essential research, technologies, translation, and applications to promote the development of gene therapy products into effective therapeutics for treating human disease—and move this revolutionary field forward. The Journal is led by a world-renowned Editorial Board with Editor-in-Chief James M. Wilson, MD, PhD at the helm; HGT Methods Editor Thierry VandenDriessche, PhD; and HGT Clinical Development Editor Barry J. Byrne, MD, PhD.
Human Gene Therapy is the Official Journal of 9 international societies, including SFTCG.
SFTCG members can access the Journal via the member website, and we encourage members to recommend the expanded Human Gene Therapy program to their library or institution to facilitate collaboration with colleagues. In addition, all SFTCG members are given the option to receive Genetic Engineering & Biotechnology News on a complimentary basis by filling out a simple qualification form.
Human Gene Therapy was voted one of the most influential journals in Biology and Medicine over the last 100 years by the Biomedical & Life Sciences Division of the Special Libraries Association. Read a free issue of Human Gene Therapy online.
The Journal welcomes your manuscript submissions. All accepted papers are published online ahead of print.
Latest Impact Factor: 4.218
2011 Journal Citation Reports® published by Thomson Reuters, 2012